Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04249505 · ClinicalTrials.gov registry record
Refractive Accuracy of "2WIN" and Portable Autorefractors
A clinical trial, sponsored by Alaska Blind Child Discovery.
- Completed
- Registry status
- 708
- Enrollment target
NCT04249505: Completed study, sponsored by Alaska Blind Child Discovery.
NCT04249505 is a clinical trial that has completed, run by Alaska Blind Child Discovery. The registered enrollment target is 708 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04249505 has completed, sponsored by Alaska Blind Child Discovery.
- COMPLETED
- Registry status
- 708 participants
- Enrollment target
Study Summary
Youth and some adults have photoscreening refractions and hand-held auto refraction before cycloplegia refraction during new and follow up eye examinations. Vector math is applied to each refraction to determine how closely the hand-held "dry" devices match actual refraction.
Primary Outcome
spherical equivalent
Interventions
- DEVICE "2WIN" Photoscreener
- DEVICE "Plusoptix A12"
- DEVICE "Retinomax"
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 708 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2021-04-01 |
What the finished NCT04249505 record still lists
NCT04249505 is an observational study that tracks outcomes without assigning an intervention. The registered 708 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which "2WIN" Photoscreener is the first listed.
NCT04249505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04249505 about?
NCT04249505 is a clinical study titled "Refractive Accuracy of "2WIN" and Portable Autorefractors". Youth and some adults have photoscreening refractions and hand-held auto refraction before cycloplegia refraction during new and follow up eye examinations. Vector math is applied to each refraction to determine how closely the hand-held "dry" devices match actual refraction.
What is the current status of trial NCT04249505?
This trial is currently completed. The enrollment target is 708 participants. The study started on 2020-01-09. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04249505?
The interventions under investigation include: "2WIN" Photoscreener (DEVICE), "Plusoptix A12" (DEVICE), "Retinomax" (DEVICE).
Who is sponsoring clinical trial NCT04249505?
This trial is sponsored by Alaska Blind Child Discovery, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI